Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Alkermes Community
NasdaqGS:ALKS Community
3
Narratives
written by author
1
Comments
on narratives written by author
9
Fair Values set
on narratives written by author
Create a narrative
Alkermes
Popular
Undervalued
Overvalued
Community Investing Ideas
Alkermes
AN
AnalystHighTarget
Consensus Narrative from 16 Analysts
Advanced CNS Treatments Will Meet Rising Mental Health Demands Despite Patent Risks
Key Takeaways Strong proprietary product growth and focused operational efficiency drive expanding margins and position Alkermes for sustained profitability. Advancing orexin agonist programs and a robust pipeline offer significant opportunities in neuropsychiatric markets, fueling diversified long-term growth.
View narrative
US$53.31
FV
51.0% undervalued
intrinsic discount
3.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
1
users have followed this narrative
4 days ago
author updated this narrative
Alkermes
AN
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
Phase Trials Will Boost ALKS 2680 And Psychiatry Amid Risks
Key Takeaways Alkermes' strategic sales force expansion and positive clinical trial results could enhance market penetration and drive revenue growth for key psychiatric products. Strong financial footing and US-based manufacturing shield Alkermes from regulatory risks, protecting margins and boosting shareholder value.
View narrative
US$41.44
FV
36.9% undervalued
intrinsic discount
-2.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
4 days ago
author updated this narrative
Alkermes
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Regulatory Scrutiny And Narrow Portfolios Will Erode US Biotechs Stability
Key Takeaways Heavy reliance on a narrow drug portfolio and key patents increases vulnerability to generic competition and exposes earnings to accelerated decline. Future growth is threatened by high regulatory risk, clinical trial failures, and shifting treatment trends reducing long-term revenue diversification and operating leverage.
View narrative
US$30.00
FV
12.9% undervalued
intrinsic discount
-4.11%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
11 days ago
author updated this narrative
Your Valuation for
ALKS
ALKS
Alkermes
Your Fair Value
US$
Current Price
US$26.13
35.0% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-274m
2b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.6b
Earnings US$372.7m
Advanced
Set Fair Value